ONCOLINX
Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy. The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world— concurrently developing ADCs across 30 different cancer indications. Oncolinx aims to enter clinical trials with a partnered program in mid-2017.
ONCOLINX
Industry:
Biotechnology Health Care Medical
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.oncolinx.com
Total Employee:
1+
Status:
Active
Contact:
+44 2035141013
Email Addresses:
[email protected]
Total Funding:
1.06 M USD
Technology used in webpage:
Font Awesome Domain Not Resolving Apache AJAX Libraries API Wix Wix DNS
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Enlibrium
Enlibrium is a developing novel drugs
Oncovaxine
Oncovaxine develops Cancer Vaccine.
Praxis Precision Medicines
Praxis Precision Medicines offers drug development services.
Current Employees Featured
Founder
Investors List
43North
43North investment in Seed Round - Oncolinx
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Oncolinx
MassChallenge
MassChallenge investment in Non Equity Assistance - Oncolinx
Official Site Inspections
http://www.oncolinx.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
